Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SN-2310
- Development stage
- Discontinued
- Lead developer
- Achieve Life Sciences
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
SN-2310 is an injectable emulsion formulation of SN-38 (7-ethyl-10-hydroxycamptothecin), the active metabolite of the widely used chemotherapeutic irinotecan. Developed by Sonus Pharmaceuticals using its proprietary TOCOSOL vitamin E-based delivery technology, SN-2310 was designed to provide direct systemic delivery of SN-38, thereby bypassing the variable and often inefficient hepatic conversion required for irinotecan. As a potent inhibitor of DNA topoisomerase I, SN-38 stabilizes the cleavable complex between the enzyme and DNA, leading to lethal double-strand DNA breaks during replication. SN-2310 was evaluated in Phase 1 clinical trials for the treatment of advanced solid malignancies, demonstrating an improved safety profile and reduced toxicity compared to irinotecan. However, following the merger of Sonus Pharmaceuticals with OncoGenex (now Achieve Life Sciences), development of the candidate was discontinued.
- Other names
- SN-38 injectable emulsionSN38 injectable emulsionSN 38 injectable emulsionSN2310 Injectable EmulsionSN-2310 Injectable EmulsionSN 2310 Injectable Emulsion
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on SN-2310.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SN-2310.